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Abstract
Background: MicroRNAs (miRNAs) are a class of small regulatory RNAs that target sequences in messenger RNAs
(mRNAs) to inhibit their protein output. Dissecting the complexities of miRNA function continues to prove
challenging as miRNAs are predicted to have thousands of targets, and mRNAs can be targeted by dozens of
miRNAs.
Results: To systematically address biological function of miRNAs, we constructed and validated a lentiviral miRNA
expression library containing 660 currently annotated and 422 candidate human miRNA precursors. The miRNAs
are expressed from their native genomic backbone, ensuring physiological processing. The arrayed layout of the
library renders it ideal for high-throughput screens, but also allows pooled screening and hit picking. We
demonstrate its functionality in both short- and long-term assays, and are able to corroborate previously described
results of well-studied miRNAs.
Conclusions: With the miRNA expression library we provide a versatile tool for the systematic elucidation of
miRNA function.
Background
MicroRNAs (miRNAs) were discovered as a class of
small regulatory molecules ten years ago [1-3]. These
~21 nucleotide (nt), small RNAs recognize partially
complementary sequences on target mRNAs [4,5]. Fol-
lowing the initial discovery of miRNAs, substantial effort
has gone into characterization of the canonical miRNA
pathway [6,7] and into miRNA discovery; by identifying
miRNAs in more species and by adding to the list of
known miRNAs [8]. Although cDNA cloning and north-
ern blotting techniques can be used to detect the most
abundant miRNAs, the advent of massively parallel
sequencing technologies has propelled the miRNA field,
allowing for both discovery and quantification of all
miRNAs in a given sample [9,10].
With the bulk of the miRNAs revealed in commonly
studied species, the next challenge lies in elucidating the
biological processes in which miRNAs play a role. Cur-
rent bioinformatic approaches rely on the identification
of partially complementary sequences in mRNAs to pre-
dict miRNA targeting. Yet these approaches still come
with one limitation; the exact parameters governing tar-
geting remain unknown. Several prediction algorithms
have been developed to overcome this difficulty by
ascribing different weights to key parameters, such as
binding energy between target and miRNA, conservation
of the target site, quality of the “seed pairing”, et cetera
[11]. Still no single algorithm emerges as the best per-
former [12], and most algorithms predict thousands of
targets for each miRNA [13]. Combining different target
prediction algorithms generates shorter list of targets by
creating more stringent cut-offs. This can provide some
enrichment in true positives, but at the cost of more
false negatives [14]. In addition to bioinformatics predic-
tion, several approaches to genome-wide experimental
miRNA target identification have been developed. These
experiments utilize Argonaute pull-down assays (HITS-
CLIP and PAR-CLIP) [15,16], changes in mRNA levels
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[17], and protein expression after introduction or abla-
tion of a specific miRNA [18-20]. These studies support
that miRNAs indeed function by targeting hundreds of
genes. Still, it is a daunting task to derive a function for
a miRNA from these long lists of potential target genes.
Despite progress in systematic approaches to find sets of
related gene that are enriched within these long target
lists [21], we are still far from satisfactory in silico pre-
diction of miRNA function.
Alternatively, differential expression of a miRNA is
commonly used to infer its function [22,23]. Identifica-
tion of conditions where a specific miRNA is expressed
versus an opposing condition where it is not, offers
some clues as to the potential action of the miRNA.
While this approach has been very successful in leading
investigators to uncover miRNA functions, it still
requires direct experimentation to prove effects due to
miRNA activity beyond providing an only coincidental
biomarker.
Another approach to determine the function of a
miRNA is by knocking it down [24-26], or knocking it
out, of the genome of a model organism [27-29]. Experi-
mental knockdown of miRNAs may confirm or invali-
date predicted functions, but it requires prior knowledge
where a miRNA is expressed. Even with this knowledge,
sufficient knockdown to demonstrate an observable
effect is not guaranteed. Complete knockout delivers a
clean result, but may not result in an obvious pheno-
type. Adding to this challenge is the possibility that
many miRNAs may elicit only subtle changes or are
redundant with other family members entirely. Indeed,
only a fraction of all C. elegans miRNA families display
pronounced abnormal phenotypes when deleted [30].
Given these challenges, knocking out a miRNA in mice
or in a human cell line may often prove a fruitless
endeavor.
In order to unravel the functions of specific miRNAs,
while overcoming much of the challenges discussed
above, we proposed to introduce or overexpress miR-
NAs in a system of interest. Moreover, we argue that it
is more efficient to examine the effect of any miRNA
for a predetermined phenotype, rather than blindly
investigating one miRNA at a time. Such screens have
been performed on different scales. Most are based on
transfection of miRNA mimics [31]; synthetic RNAs
that usually have a modified backbone. Although this
approach ensures the presence of the mature miRNA in
the target cells, a miRNA mimic is not processed via the
canonical miRNA biogenesis pathway. This multi-clea-
vage process starts with the recognition of a hairpin in
the primary transcript and ends with a mature miRNA
produced from one or both of the arms of the hairpin
[32]. Bypassing this physiological processing step has
several implications. For instance, several variants of a
miRNA from the same primary transcript can arise due
to variations in the processing pathway, such as arm
switching, non-templated additions of adenines or ura-
cils, and variations in the 3’ and 5’ cleavage sites [33,34].
Besides the loss of miRNA variants, the most-widely
used miRNA mimics have modified backbones to
increase stability within the cell. Consequently, they are
not cleared naturally from the cells as endogenous miR-
NAs. Furthermore, it is possible that miRNA mimic
transfection achieves cellular concentrations beyond
physiological relevance. On the other hand, loading into
the RISC complex, which is essential for biological activ-
ity, is not necessarily efficient for mimic transfection, as
this process is known to be coupled to hairpin proces-
sing [35,36]. To express transcripts for endogenous pro-
cessing into mature miRNAs, plasmid [37] or viral
vectors [38,39] can be employed. While the retroviral
library described by Agami and colleagues is a valuable
tool for miRNA functional screens in pooled format, the
viral supernatants are not available as individual isolates
amenable to arrayed high-throughput screens [38].
Here, we describe the construction and application of
a lentiviral human miRNA expression library. This
library contains 660 annotated human miRNAs and 422
candidate miRNAs [10,40]. All are expressed from their
genomic backbone, ensuring physiological processing of
the miRNAs. The library is organized for high-through-
put screening to provide a resource for the systematic
elucidation of miRNA function. In addition, all lentiviral
miRNA expression constructs can be applied individu-
ally to evaluate primary results. Lastly, we demonstrate
the utility of this library in various types of screens to
present the miRNA expression library as a versatile tool
to study miRNA function.
Results and Discussion
Approach and setup
We aimed for the construction of a miRNA expression
library that fulfills four criteria: 1) the library contains
all human miRNAs; 2) each miRNA is represented in a
separate stock to allow for arrayed screening; 3) the
library can be used over a wide range of different cell
types; 4) the miRNAs are swiftly and stably overex-
pressed. The first two criteria will be discussed below.
The third and fourth criteria were met by choosing a
lentiviral expression system, employing the pCDH vec-
tor. The lentiviral particles express VSV-G, a glycopro-
tein that grants broad tropism [41]. The glycoprotein’s
receptor is a lipid component of the plasma membrane
that occurs on most cell types over a wide range of spe-
cies. Lentiviruses integrate into the host genome [42],
but unlike other retroviruses, lentiviruses do not require
cell division for genomic integration [43,44]. For
instance, the lentivirus is able to transduce quiescent
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stem cells and terminally differentiated neurons [43]. By
integrating into the host genome, the construct is
retained through cell divisions and can be stably
expressed for an indefinite period of time. We chose a
lentiviral backbone with a puromycin-resistance cassette
to be able to select for successfully transduced cells [45].
To create a comprehensive library containing all
human miRNAs, we included all miRNAs known at the
time we started composing the library. We obtained
genomic loci from the widely adopted miRBase miRNA
repository (version 14) [46]. We also included a set of
candidate miRNAs from previous experiments [10,40].
Although we did not update the library after viral parti-
cles for the entire library were produced, some of the
candidate miRNAs have since entered the registry. See
additional file 1, table S1 for a list of the current annota-
tion of all miRNAs in the library.
All miRNA loci, containing the full-length hairpin and
~100 nt flanking sequence on each side, were cloned
into pCDH behind the CMV promoter. Care was taken
to clone each miRNA separately, even when this
miRNA resides in close proximity to another miRNA.
After construction of the plasmid library, all constructs
were packaged into lentiviral particles and portioned
into individual tubes organized in ready-to-use 96-well
format; the fact that tubes can be accessed separately
adds versatility to the library. All virus supernatants
were concentrated to titers of ~5*108 IFU/mL, in order
to achieve efficient transduction with only small
volumes of virus supernatant. This eliminates the need
for infection under centrifugation or replacement of
medium with virus-conditioned medium. While lenti-
viral particles were produced for all constructs individu-
ally, it should be mentioned the original plasmid library
can also be applied in its own right. It can also be used
for plasmid-based screens, recloning purposes, or to
create a pool of constructs containing all or a subset of
miRNA constructs for generating mixed lentiviral
stocks. Figure 1 is a schematic of the library construc-
tion and its most important features.
Library validation
The first step in the characterization of the library is the
determination of transduction efficiency and optimal
titration of the lentiviral particles. To this end, we used
a variant of pCDH containing a GFP cassette in place of
the puromycin-resistance cassette. We infected A375
melanoma cells with different virus concentrations, in
combination with several concentrations of polybrene.
While transduction efficiency reached over 90% under
several conditions, increased amounts of virus led to
brighter GFP expression within the population of cells
(Figure 2a). This indicates multiple copies are integrated
per cell when using higher titers. GFP expression was
higher at 72 hours after infection than after 48 hours.
This implies 72 hours post infection is a more sensitive
time point for determination of transduction efficiency,
rather than earlier timepoints. We further optimized
conditions for virus infection in a panel of seven cell
lines (Figure 2b). Notably, this panel includes the diploid
fetal lung fibroblast line IMR-90; a non-transformed cell
line [47]. Optimal transduction efficiencies were reached
between 106 and 107 IFU/mL.
As mentioned, lentivirus is a favorable vector for its
ability to transduce cells that are hard to transfect, such
as stem cells. We have successfully transduced primary
human intestinal cells using a GFP-encoding vector.
These cells were subsequently used to create intestinal
organoids in vitro [48]. After prolonged culture, entire
organoid bodies turned fluorescent, indicating the stem
cells from which the organoids developed were also suc-
cessfully transduced (Figure 2c).
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Figure 1 Overview of the miRNA library. (A) 660 annotated and 422 candidate miRNAs were cloned from their genomic loci into a lentiviral
expression construct. From each construct, an individual batch of virus supernatant was created and portioned into individual tubes organized
in a 96-well format. (B) Overlap between miRNAs included in the lentiviral library and miRNAs annotated in version 14 and version 17 of
miRBase. The library contains constructs with variants or duplicates of some miRNA loci, which brings the total to 1120 constructs.
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While ectopic expression of GFP is useful to deter-
mine transduction efficiency, it does not address
whether miRNAs are also successfully overexpressed.
We used a panel of ten test miRNAs to assess miRNA
overexpression in five human cell lines: PC-3 (prostate
cancer), MDA-MB-231 (breast cancer), A549 (lung can-
cer), IMR-90 (fetal lung fibroblast), and MCF-7 (breast
cancer). Cells were infected with 1.0*107 IFU/mL and
subjected to puromycin selection from 24 hours after
infection. RNA was collected 48 hours (MCF-7), 72
hours (PC-3, MDA-MB-231 and A549) or 96 hours
after infection (IMR-90). Relative mature miRNA
expression was measured by qPCR. Values were standar-
dized against the corresponding cell line infected with
an empty vector control. We were able to overexpress
all miRNAs in all cell lines, with the exception of miR-
221 in IMR-90 cells (table 1). The fact that miR-221 is
very effectively overexpressed in MCF7 indicates the
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Figure 2 Transduction efficiencies in different cell systems. (A) A375 cells were infected with different amounts of GFP-encoding virus and
different concentrations of polybrene. GFP intensity of each cell was measured after 48 hours and 72 hours. The graphs on the right summarize
the GFP intensities of each population in the corresponding row. (B) Transduction efficiency of GFP-encoding virus for several cell lines. For all
cell lines tested, transduction efficiencies above 80% were achieved. (C) Successful transduction of human intestinal stem cells with GFP-
encoding virus. Infected stem cells were able to grow out into three-dimensional intestinal organoids in Matrigel. Below: magnification of inlay.
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expression construct is functional. Besides, we were able
to overexpress all other miRNAs in IMR-90. The results
with miR-221 can at least partially be ascribed to very
high endogenous miR-221 levels in this cell line (addi-
tional file 2, table S2) and also suggest that overexpres-
sion of miRNAs using our standard conditions remains
within physiological levels.
Next, we examined miRNA expression kinetics after
infection. To determine the optimal conditions for a
screen, such as assay length and virus titer, it is impor-
tant to know when and to what level the miRNA will be
expressed. We have tested this extensively for let-7a and
miR-372 in A375 cells. While let-7a is abundant in
these cells, miR-372 is barely detectable (Figure 3). Both
expression profiles show a quick surge of miRNA
expression within 4 hours after infection. The early
source of these miRNAs is unclear, but they may have
been present in the virus supernatant, encapsidated
within the virus, or processed intracellularly from the
viral RNA genome. miRNA levels exhibit a slight drop,
but are quickly overtaken by expression from integrated
constructs 16 to 20 hours after infection. Our data
demonstrate that already after 24 hours, ectopic expres-
sion of miRNAs reaches comparable levels of endogen-
ously predominant miRNAs, as evident from the
expression relative to endogenous let-7a and U6 RNA
(Figure 3b).
For long-term experiments, it is necessary for miRNA
expression to be sustained. 72 hours after infection with
let-7a or miR-372, we passaged A375 cells and cultured
them either with or without puromycin selection. We
examined miRNA expression by miRNA qPCR at 5, 9
and 20 days after infection (Figure 3c). A decline in
miRNA expression was observed with both miRNAs
between day 3 and day 5 after infection. This may be
caused either by passaging or changed culture conditions,
but it is also possible that it is a secondary effect of highly
elevated miRNA processing. This effect was markedly
stronger in the let-7a-infected cells, which may indicate
that there is a selection disadvantage for cells with high
let-7a expression. Despite the small drop after three days,
overexpression of both miRNAs stabilized and persisted
for weeks. Even after prolonged culture without puromy-
cin selection, miRNA overexpression was sustained. We
conclude there is little or no genetic loss or epigenetic
silencing of the integrated construct.
As the goal of the library is to identify biologically
relevant functions of miRNAs, we performed a proof-of-
principle experiment by testing the well-documented
effects of let-7a [49-51] as an inhibitor of cell
Table 1 Overexpression of miRNAs in various cell lines
after lentiviral transduction
microRNA cell line
PC-3 MDA-MB-231 A549 IMR-90 MCF7
miR-221 5.0 3.1 8.7 0.7 527
miR-203 > 1, 000 > 1, 000 > 1, 000 > 1, 000 45.6
miR-21 4.7 2.2 3.1 3.0 3.0
let-7a 11.8 114 18.9 17 38.3
miR-372 > 1, 000 > 1, 000 > 1, 000 > 1, 000 > 1, 000
miR-34a > 1, 000 > 1, 000 26.0 17.6 170
miR-126 > 1, 000 > 1, 000 220 > 1, 000 293
miR-10b > 1, 000 > 1, 000 321 406 > 1, 000
miR-335 > 1, 000 > 1, 000 > 1, 000 > 1, 000 > 1, 000
miR-205 > 1, 000 > 1, 000 14.1 > 1, 000 159
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Figure 3 miRNA overexpression kinetics. A375 cells were infected with either let-7a or miR-372-encoding virus and expression was measured
by miRNA qPCR. (A, B) Expression of let-7a and miR-372 is measured 0, 4, 12, 24 and 72 hours after infection. Data is plotted as fold
overexpression (A) or relative to U6 snRNA expression (B). (C) Three days after infection, samples were passaged and cultured either with or
without puromycin selection. Expression of let-7a and miR-372 was measured 5, 9 and 20 days after infection. For both miRNAs, expression
dipped after three days but stabilized thereafter, resulting in a sustained overexpression.
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proliferation and miR-372 [38] as a stimulator in five
cell lines. The experiment was set up in the fashion of a
high-content screen. Cells were seeded in 384-well
plates and infected after 8 hours. 72 hours after infec-
tion, cells were fixed and nuclei were stained with
Hoechst. The automated image analysis software not
only counts the number of nuclei, but also detects aber-
rations in nuclear shape and condensed chromatin
(Figure 4). Although we did not find any novel effects of
the miRNAs on nuclear shape, we were able to confirm
the expected effects of let-7a and miR-372 on prolifera-
tion in a high-content setup.
Clonal screening
As a first use of the complete library we screened miR-
NAs for their effect on A375 melanoma cell
empty vector miR-372 let-7a
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Figure 4 Lentiviral transduction of miRNAs in a high-content setup. Five different cell lines were infected with either empty vector miR-372,
or let-7a. Cells were fixed 96 hours after infection and stained with Hoechst. Samples were analyzed with automated image analysis software.
Four parameters were assessed: 1, number of nuclei per field; 2) nuclear size; 3) nuclear shape; 4) chromatin condensation. Graphs on the right
show the quantification of the number of nuclei per field. Error bars represent standard deviations of triplicate wells. Four fields were counted
per well.
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proliferation. We tested whether we could detect prolif-
eration effects in A375 cells in a 96-well setup, again
using let-7a and miR-372 as test miRNAs. The effects
were highly similar to those seen in Figure 4 (Figure 5a).
Every single well infected with either let-7a or miR-372
proved a statistical outlier compared to empty-vector
transduced wells (Figure 5a, right panel).
For the entire library, we performed an arrayed screen
by MTS assay, which measures the viability of cells in a
well [52]. This measure is reported to correlate strongly
with cell number. All samples were tested in duplicate,
and for each replicate a B-score was calculated [53].
This method calculates how a miRNA scores relative to
the other miRNAs on the same plate. It is a robust
method as it is not sensitive to outliers. B-scores of
replicates are shown in Figure 5b. Also shown are the
measures for all let-7a constructs and miR-372. The
strong correlation between replicates indicates a high
reproducibility of the assay. The effects of let-7a and
miR-372 are similar as in the cell count assay. Impor-
tantly, all let-7a constructs cluster together. Since these
constructs have different backbones but produce the
same mature miRNA, we surmise the observed effects
are likely to be caused by the mature miRNA. A con-
founding factor in short-term arrayed screens can be the
range of virus titers of the different constructs. However,
we saw no correlation between virus titer and cell viabi-
lity (additional file 3, figure S1). Thus, with these
experimental conditions, virus titers were not a signifi-
cant factor contributing to toxicity.
Pooled screening
Some assays do not lend themselves to screening in 96-
well format. In such cases the lentiviral library can be
used for a pooled screen. There are two approaches: pool
virus supernatant of several or all constructs together, or
infect cells with the individual constructs and subse-
quently pool cells. The latter is generally favorable,
because it precludes the possibility that two or more
virus particles containing different miRNAs infect a sin-
gle cell. A puromycin selection step can be added to
make certain each construct is represented in transduced
cells and to reduce background caused by non-trans-
duced cells. We applied this approach to the poorly inva-
sive HCT15 colorectal cell line. HCT15 cells were
individually infected, puromycin-selected, and pooled in
groups of 40 constructs. A fraction of the pool was used
for genomic DNA isolation and the rest was subjected to
two rounds of an invasion assay. Cells that successfully
transmigrated through extracellular matrix were subcul-
tured and genomic DNA was isolated. To identify the
miRNA constructs that were enriched in the transmi-
grated fraction, we took advantage of the fact that the
constructs are integrated into the host genome. We PCR-
amplified the constructs from the genomic DNA using
universal primers that anneal to the vector backbone
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Figure 5 Arrayed screening using the lentiviral library. (A) A375 cells were seeded in a 96-well plate and infected with virus containing an
empty vector, let-7a, or miR-372. Five days after infection, cells expressing let-7a were significantly less numerous than cells expressing empty
vector, while cells expressing miR-372 were significantly more numerous (left panel, * indicates p < 10-4 in a two-tailed t-test). Values are average
number of cells per well ± standard deviation, n = 6. Each measurement of both let-7a and miR-372 samples is separated from the empty
vector samples by more than three standard deviations (Z-score, right panel). (B) Results of an arrayed screen on cell viability of A375 cells. Cells
in individual wells were infected with single miRNA constructs and subjected to an MTS assay 5 days after infection. The screen was performed
in duplicate. For each measurement a B-score was calculated. Correlation between duplicate B-scores is shown. The green dots represent let-7a-
1, -2, and -3, while the red dot represents miR-372.
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(Figure 6a). The PCR products were subjected to high-
throughput sequencing. Relative abundance of the var-
ious constructs was derived from the sequence reads
mapping to them. Hits were selected on the basis of a
weighted score calculated from the enrichment and the
number of sequence reads in the invasive fraction. We
found evidence for 45 miRNAs that may enhance the
invasive capacity of HCT15 cells (Figure 6b).
In a pooled invasion screen, as performed above, the
possibility exists that a portion of the hits can be
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Figure 6 A pooled screen for invasive capacity of miRNAs using the lentiviral library. (A) Schematic of the pooled invasion screen setup.
In brief, after clonal infection (not shown here), cells with 40 individual miRNA constructs were pooled and either subjected to two rounds of an
invasion assay or used as the control fraction. Of both fractions, integrated constructs were quantified by massively parallel sequencing to
determine enrichment. (B) miRNAs were chosen for confirmation based on a combination (E × R > 1) of enrichment (E) after invasion and their
abundance in the invasive fraction; expressed as the scaled number of reads (R). 23 out of 45 miRNAs were confirmed to enhance invasive
capacity of HCT15 cells in final individual invasion assays.
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“passenger hits” that do not impart invasive capacity,
but are present in cells that trail the truly invasive cells
as they make their way through the extracellular matrix.
To distinguish these two types, we subjected each hit
individually to an invasion assay. We were able to con-
firm 23 miRNAs that increase invasiveness of HCT15
cells (Figure 6b).
Conclusions
We present a lentiviral miRNA expression library that is
optimized for use in arrayed screens. The library allows
miRNAs to be individually assessed in any gain-of-func-
tion screen. We envision the library being used in a
wide range of functional screens. To name some possi-
bilities: reporter-based assay screens, screens to study
cell cycle, senescence, and epithelial-to-mesenchymal
transition. The broad tropism of the lentivirus makes it
applicable to infect cells of different species. This may
prove particularly valuable, since lentivirus can be
directly used in vivo [43]. Thus, the same lentivirus can
be used to screen for a miRNA function in vitro and
verify this functionality in vivo.
We have demonstrated the transduction of stem cells
that were subsequently used for in vitro organ culture.
The ability to stably transduce stem cells opens up ave-
nues for studying miRNAs required for differentiation
and stemness.
An arrayed library comes with several advantages.
Arrayed screening offers more sensitivity and faster
results than pooled screening, without the need of data
deconvolution. It also allows for the assessment of sev-
eral more complex parameters, as is commonplace in
high-content screens. Assays that require long-term cul-
ture may not be amenable to arrayed screening and
require pooling. Still, infecting cells individually before
pooling is likely to decrease false-negative results in
pooled screens, suggesting that even for pooled screens
an arrayed library may be preferred.
Our library currently contains the majority of all
human miRNAs. However, the most recent update (ver-
sion 17) of miRBase includes a large number of newly
identified miRNAs. While we do not wish to question
their validity or understate their potential, we argue that
most miRNA functions will be covered by the most
highly expressed or broadly conserved miRNAs, which
were already present in earlier versions of miRBase and
thus represented in our library. By the same token, the
merit of candidate miRNAs in our library can be ques-
tioned. In anticipation of this, candidate miRNAs were
positioned on separate plates in the library, presenting
researchers the choice to screen the entire library, only
the annotated miRNAs, or only the candidate miRNAs.
Expression of the miRNAs from their native genomic
background ensures the physiological processing of the
miRNA. Not only the pre-miRNA hairpin, but also the
flanking sequence contributes to proper processing [54].
Transcribing the miRNA from an integrated construct
enables expression of both arms and all isomiRs that
would naturally derive from the primary transcript.
Therefore, the library could be employed for further
characterization and validation of the included miRNAs.
Such experiments have been extensively done for mouse
miRNAs [55], but not for human miRNAs.
We have shown that ectopic expression of miRNAs
using a lentiviral vector can be used to screen for biolo-
gically relevant effects. While the library is widely
applicable and can be used to study various aspects of
biology, our primary focus is on cancer-related pro-
cesses. A first screen assessing miRNA-induced effects
on melanoma cell growth demonstrated the value of the
library in an arrayed screen. The next step is to perform
such screens over a panel of cell lines to determine
which miRNAs may have a growth effect on specific
cancer indications, and which miRNAs have a general
growth inhibitory or stimulatory function. These results
will aid in finding miRNAs suited for tumor-specific
treatment. Indeed, such therapeutic options have been
successfully explored in a murine model of hepatocellu-
lar carcinoma [56]. With the miRNA expression library,
we offer a platform that facilitates the identification of
miRNAs with therapeutically relevant functions.
Methods
Construction of the lentiviral library and other constructs
Backbone for all constructs in the library is the lentiviral
expression construct pCDH (cat. no. CD510B-1, System
Biosciences). Individual loci containing a single miRNA
hairpin were PCR amplified from human genomic DNA
and cloned into the multiple cloning site of the plasmid.
Loci were either obtained from miRBase http://mirbase.
org/ or from mapping of candidate miRNAs found in
previous experiments [10,40]. Primers were designed
using Primer3. PCR was performed using Pfu polymer-
ase (Agilent). The cloned fragments contain the full-
length miRNA hairpin and approximately 100 flanking
base pairs on both sides. An expression construct with
EGFP was cloned by excision and ligation of the EGFP
sequence from pEGFP-N1 (Clontech) into the multiple
cloning site of pCDH. All constructs were packaged into
lentiviral particles commercially by System Biosciences
using the pPACKH1 HIV-based lentiviral packaging kit
(cat. no. LV500A-1, System Biosciences). Viral particles
were recieved in concentrated form with a median titer
of 5.9*108 IFU/mL in a 96-well format. Sequence of all
inserts was confirmed from both the plasmid and the
virus supernatant (we were able to obtain high-quality
specific sequences from the virus supernatant using uni-
versal primers, most likely due to trace amounts of
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plasmid). A list of all included miRNAs in their current
annotation (miRBase17) is available in additional file 1,
table S1. Lentiviral particles for pCDH with copGFP
instead of puroR (cat. no. CD511B-1) were ordered
separately from System Biosciences.
Cell culture and viral infections
293T, A375, MDA-MB-231, A549, MCF-7, IMR-90, PC-
3, and HCT15 cells were maintained on 10% FCS com-
plete medium: DMEM Glutamax (GIBCO) with 10%
FCS (Sigma) supplemented with non-essential amino
acids (GIBCO) and penicillin/streptomycin (GIBCO). All
viral infections followed by RNA isolation were done 8
hours after seeding 10, 000 cells in a 6-well plate in 2
mL 10% FCS complete medium. All transduction effi-
ciency experiments were performed by infection with
pCDH-MCS-EF1-copGFP, except for the organoid cul-
ture, for which we used pCDH-EGFP-EF1-PuroR. Infec-
tion mix contained 2 μL virus supernatant, 12 μL 1 mg/
mL polybrene (Sigma), and 86 μL PBS0, unless stated
otherwise. Intestinal organoid bodies were cultured as
described before [48]. Because the organoids are grown
in Matrigel, cells were infected before seeding. Cells
were infected in 250 μL Wnt-3a-conditioned medium
containing 2 μL virus supernatant. Infection took place
during a centrifugation step at 150 rcf for 1 hour at
room temperature. Unless indicated otherwise, infec-
tions were performed in 96-well plates using the follow-
ing set-up: 1000 cells were seeded in 100 μL 5% FCS
complete medium per well of a 96-well plate and
infected after 8 hours with 10 μL infection mix. 10 μL
infection mix contained 0.6 μL 1 mg/mL polybrene, 0.5
μL virus supernatant, and 8.9 μL PBS0. In the arrayed
screen, medium was replaced with 150 μL fresh medium
24 hours after infection.
MTS assay
Five days after infection, 30 μL MTS One Solution (Pro-
mega) was added to all samples. After each hour, plates
were gently tapped to disperse the coloration of the
MTS, and absorbance was measured at 492 nm. Last
measurements were taken 4 hours after start of the
assay. The time point with measurements showing the
highest dynamic range without saturation of signal was
used for data analysis.
Nuclear staining, GFP quantification and high-content
applications
Five days after infection, 100 μL 8% PFA (Sigma) was
added to all samples. Cells were fixed for 15 minutes.
Samples were washed once with PBS0 followed by 10
minutes staining in 100 μL PBS0 containing 0.5 μg/mL
Hoechst 33342 (Sigma). Cells were washed twice with
PBS0 and kept on PBS0 at 4°C. Cells were quantified on
a Cellomics ArrayScan VTI using the accompanying
software by counting nuclei in 4 fields per well under
10× magnification. Nuclei were identified as shapes with
a contiguous Hoechst stain. Nuclear demarcations were
used to quantify GFP intensity. All data acquisition was
done using adaptions of the TargetActivation program
of the ArrayScan software. Data and images displayed in
table 1 and Figure 4 were generated by Cenix
BioScience, GmbH.
RNA isolation and miRNA qPCRs
RNA was isolated using TRIzol (Invitrogen) isolation
following the manufacturer’s protocol. Small RNAs
qPCR reactions were performed using the TaqMan
MicroRNA reverse transcription kit (ABI), Taqman
MicroRNA qPCR assays (ABI) and TaqMan Universal
PCR Master Mix, No AmpErase UNG (ABI) using 10
ng total RNA input. qPCR reactions were set up using
the suggested reaction conditions on a Bio-Rad MyiQ
thermal cycler. U6 was used as a housekeeping control
RNA in the experiments concerning Figure 3, RNU6B
was used in the experiments concerning table 1. Relative
expression was calculated using the 2-ΔΔCt method.
miRNA qPCR data in table 1 were generated by Cenix
BioScience GmbH.
Invasion assay
HCT15 cells were seeded at 2500 cells per well in a 96-
well plate in 10% complete medium. Cells were infected
with individual virus supernatants (0.5 μL per well) after
24 hours. 72 hours after infection cells were selected
with puromycin-containing medium and subsequently
grown to 100% confluency. Pools were made of 40 sam-
ples per pool and grown for another 3 days on puromy-
cin-containing medium. Half of the pooled culture was
used for genomic DNA isolation, the other half was sub-
jected to two rounds of invasion assay. For each pool,
2*105 cells were applied to the upper compartment of a
Boyden chamber (BD Fluoroblok 24-Multiwell, 8 μm
pores) coated with extracellular matrix (ECM, Sigma)
and containing serum-free medium, and allowed to
invade the lower compartment containing 10% FCS
medium. Cells were collected from the bottom compart-
ment and expanded for 2-3 weeks on complete medium.
2*105 cells of this subculture were applied to a second
round of invasion as described above. Cells in the result-
ing bottom compartment were subcultured to be used
for genomic DNA isolation.
Genomic DNA isolation and massively parallel sequencing
Genomic DNA was isolated from cells using a Qiagen
Genomic Tip kit following the manufacterer’s instruc-
tions. For both the invasive fraction and the control
fraction, 10 ng DNA of each pool was pooled together
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and subjected to PCR-amplification (20 cycles) of inte-
grated constructs using Platinum PCR Supermix (Invi-
trogen) and primers flanking the inserts. In a
subsequent, secondary (3 cycles) and tertiary (3 cycles)
PCR the adapters and barcodes used for massively paral-
lel sequencing were added to the flanks of the products.
Samples were sequenced on the ABI SOLiD platform.
The invasive and control fraction yielded 1.0*106 and
0.9*106 reads that mapped to integrated constructs
respectively.
Library availability
Both the plasmid and virus library are publicly available
when requested through InteRNA Technologies. Con-
tact information is available at http://www.interna-tech-
nologies.com.
Additional material
Additional file 1: Table S1. Contains a list of the miRNAs included in
the library and their cognate genomic sequences that were cloned into
the vector, and associated virus titers.
Additional file 2: Table S2. Contains the endogenous levels of the set
of 10 test miRNAs in the five tested cell lines. Expression calculated as 2-
ΔCt relative to RNU6B.
Additional file 3: Figure S1. Demonstrates the lack of correlation
between virus titer and toxicity.
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